IHI - ETF AI Analysis

Top Page

iShares U.S. Medical Devices ETF (IHI)

Rating:74Outperform

Price Target:―

IHI, the iShares U.S. Medical Devices ETF, earns a solid overall rating thanks to several high-quality medical device leaders with strong financial performance and growth prospects. Heavily weighted holdings like Abbott Laboratories, Intuitive Surgical, Medtronic, Boston Scientific, and Edwards Lifesciences support the fund’s quality through robust earnings, innovation, and raised guidance, even though many trade at premium valuations and sometimes show mixed or bearish technical signals. The main risk is that the fund is concentrated in the U.S. medical devices sector, so industry-specific challenges, high valuations, and issues like tariffs or international headwinds at key holdings could weigh on performance.

Positive Factors

Focused Exposure to Medical Devices

The ETF gives targeted access to U.S. medical device companies, which operate in a specialized and often resilient area of health care.

Large, Established Holdings

Many of the top positions are well-known, sizable health care companies, which can offer more stability than smaller, less proven firms.

Meaningful Fund Size

With several billion dollars in assets, the ETF is large enough that it is likely to trade relatively smoothly for most everyday investors.

Negative Factors

Recent Weak Performance

The fund has shown negative returns over the past month, three months, and year to date, signaling recent weakness in its segment of the market.

Heavy Concentration in a Few Stocks

A small number of holdings make up a large share of the portfolio, which increases the impact that any one company’s poor performance can have on the ETF.

Narrow Sector and Geographic Focus

Almost all of the ETF’s assets are in U.S. health care stocks, so it offers little diversification across other sectors or regions.

IHI vs. SPDR S&P 500 ETF (SPY)

AUM3.59B

RegionNorth America

Expense Ratio0.38%

Beta0.69

IssueriShares

Inception DateMay 01, 2006

Dividend Yield0.36%

Asset ClassEquity

Index TrackedDJ US Select / Medical Equipment

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,065,431

30 Day Avg. Volume1,703,734

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

72.07

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering47

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IHI Summary

The iShares U.S. Medical Devices ETF (IHI) tracks the DJ US Select / Medical Equipment index, focusing on U.S. companies that make medical devices and equipment used in diagnostics, surgery, and patient care. It holds well-known names like Abbott Laboratories and Intuitive Surgical, giving investors a simple way to invest in the growth of healthcare technology without having to pick individual stocks. Someone might consider IHI for long-term growth and sector diversification within healthcare. A key risk is that it is heavily concentrated in medical device companies, so it can rise or fall sharply with this specific part of the market.

How much will it cost me?The iShares U.S. Medical Devices ETF (IHI) has an expense ratio of 0.38%, which means you’ll pay $3.80 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically involves more specialized management compared to broad-market passive funds.

What would affect this ETF?The iShares U.S. Medical Devices ETF (IHI) could benefit from growing demand for advanced healthcare solutions and technological innovations in medical devices, driven by an aging population and increased focus on personalized medicine. However, potential risks include regulatory changes, pricing pressures, and economic downturns that may impact healthcare spending, as well as competition among top holdings like Abbott Laboratories and Intuitive Surgical. The ETF’s focus on U.S.-based companies may also limit exposure to growth opportunities in international markets.

IHI Top 10 Holdings

IHI is a pure play on U.S. medical devices, and its story right now is a tug-of-war between a few heavyweights. Abbott and Intuitive Surgical sit in the driver’s seat by size but have been losing steam lately, putting some pressure on the fund. Boston Scientific has also been lagging, adding to the drag. On the brighter side, Stryker, GE Healthcare, and ResMed are quietly pulling their weight with steadier, rising trends. With all major holdings U.S.-based and clustered in health care equipment, this ETF is highly focused rather than broadly diversified.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ABT	Abbott Laboratories	16.65%	$600.34M	$197.00B	-16.83%	73 Outperform
ISRG	Intuitive Surgical	15.25%	$549.77M	$177.84B	-14.83%	78 Outperform
BSX	Boston Scientific	9.43%	$340.17M	$113.19B	-28.62%	79 Outperform
SYK	Stryker	5.13%	$184.91M	$144.40B	-0.67%	70 Outperform
GEHC	GE Healthcare Technologies Inc	4.76%	$171.57M	$37.80B	-7.53%	78 Outperform
RMD	Resmed	4.76%	$171.51M	$37.72B	11.84%	76 Outperform
MDT	Medtronic	4.59%	$165.38M	$126.27B	7.69%	80 Outperform
EW	Edwards Lifesciences	4.54%	$163.57M	$45.83B	8.84%	79 Outperform
BDX	Becton Dickinson	4.46%	$160.77M	$52.02B	-18.48%	67 Neutral
IDXX	Idexx Laboratories	4.32%	$155.83M	$50.70B	40.39%	78 Outperform

IHI Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price―

Price Trends

50DMA

61.16

Negative

100DMA

61.26

Negative

200DMA

61.22

Negative

Market Momentum

MACD

-0.72

Negative

RSI

47.50

Neutral

STOCH

90.65

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IHI, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 59.05, equal to the 50-day MA of 61.16, and equal to the 200-day MA of 61.22, indicating a neutral trend. The MACD of -0.72 indicates Negative momentum. The RSI at 47.50 is Neutral, neither overbought nor oversold. The STOCH value of 90.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IHI.

IHI Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IHI	―	―	$3.59B	0.38%	74 Outperform
IBB	―	―	$8.59B	0.44%	66 Neutral
XBI	―	―	$8.00B	0.35%	59 Neutral
IYH	―	―	$3.32B	0.38%	73 Outperform
FHLC	―	―	$2.95B	0.08%	72 Outperform
FBT	―	―	$2.41B	0.54%	72 Outperform

Performance Comparison

IHI

iShares U.S. Medical Devices ETF

59.36

-5.12

-7.94%

IBB

iShares Biotechnology ETF

―

XBI

SPDR S&P BIOTECH ETF

―

IYH

iShares U.S. Healthcare ETF

―

FHLC

Fidelity MSCI Health Care Index ETF

―

FBT

First Trust NYSE Arca Biotechnology Index Fund

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents